Piliou Stavroula, Farman Theo A, Marini Arianna, Manoharan Shathviga, Mastroeni Pietro
Department of Veterinary Medicine, University of Cambridge, Cambridge CB3 0ES, UK.
Department of Veterinary Medicine, University of Cambridge, Cambridge CB3 0ES, UK.
Vaccine. 2023 Dec 18;41(52):7671-7681. doi: 10.1016/j.vaccine.2023.11.034. Epub 2023 Nov 25.
An affordable, accessible, and broadly protective vaccine is required to tackle the re-occurring bacterial meningococcal epidemics in Sub-Saharan Africa as well as an effective control of multi-drug resistant strains of gonococcus. Outer membrane vesicles (OMVs) secreted from Gram-negative bacteria represent an attractive platform for antigen delivery to the immune system and therefore for development of multi-component vaccines. In this study, we describe the generation of modified OMVs (mOMVs) from commensal biosafety-level 1 (BSL-1) Neisseria cinerea ATCC® 14685, which is phylogenetically close to the pathogenic bacteria Neisseria meningitidis and Neisseria gonorrhoeae. mOMVs were prepared from N. cinerea engineered to express heterologous antigens from N. meningitidis (factor H binding protein (fHbp) and Neisseria Heparin Binding Antigen (NHBA-2)) and from N. gonorrhoeae (NHBA-542). Mice immunised with the mOMVs produced antibodies against fHbp and NHBA. The work indicates that mOMV from N. cinerea can be used as a platform to induce immune responses against antigens involved in the protective immune response against meningococcal and gonococcal diseases.
需要一种价格合理、易于获取且具有广泛保护作用的疫苗来应对撒哈拉以南非洲地区反复出现的细菌性脑膜炎球菌疫情，以及有效控制淋病奈瑟菌的多重耐药菌株。革兰氏阴性菌分泌的外膜囊泡（OMV）是一种有吸引力的抗原递送至免疫系统的平台，因此也是开发多组分疫苗的平台。在本研究中，我们描述了从共生生物安全1级（BSL-1）的灰色奈瑟菌ATCC® 14685产生修饰的OMV（mOMV），该菌株在系统发育上与病原菌脑膜炎奈瑟菌和淋病奈瑟菌相近。mOMV是由经过基因工程改造的灰色奈瑟菌制备而成，该菌株可表达来自脑膜炎奈瑟菌的异源抗原（因子H结合蛋白（fHbp）和奈瑟菌肝素结合抗原（NHBA-2））以及来自淋病奈瑟菌的抗原（NHBA-542）。用mOMV免疫的小鼠产生了针对fHbp和NHBA的抗体。这项工作表明，来自灰色奈瑟菌的mOMV可作为一个平台，诱导针对参与脑膜炎球菌和淋球菌疾病保护性免疫反应的抗原的免疫反应。
